

Literatur zur CME:

***Colitis ulcerosa* – aktuelles klinisches Management**

Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. *Inflamm Bowel Dis* 2013;19(7):1384-9

Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. *Gut* 2006;55(1):47-53

Bokemeyer B, Lakomek H. Rheuma und chronisch-entzündliche Darmerkrankungen. *Arthritis und Rheuma* 2018;38(01):22-6

Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. *Aliment Pharmacol Ther* 2018;47(4):454-65

Butter M, Weiler S, Biedermann L, et al. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. *Maturitas* 2018;110:71-8

Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. *Aliment Pharmacol Ther* 2017;46(1):3-15

Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. *Aliment Pharmacol Ther* 2017;45(10):1291-302

Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2011;9(1):30-5

ECCO e-Guide ECsACO. ECCO e-Guide: interventions. 2016. <http://www.e-guide.ecco-ibd.eu/interventions>, abgerufen am: 24.05.2018

European Medicines Agency. Tofacitinib. 2018. <http://www.ema.europa.eu>, abgerufen am 17.09.2018

Fachinformation. Adalimumab. 2018a. <https://www.fachinfo.de>, abgerufen am: 02.07.2018

Fachinformation. Golimumab. 2018b. <https://www.fachinfo.de>, abgerufen am: 02.07.2018

Fachinformation. Infliximab. 2018c. <https://www.fachinfo.de>, abgerufen am: 02.07.2018

Fachinformation. Vedolizumab. 2018d. <https://www.fachinfo.de>, abgerufen am: 11.06.2018

Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013;369(8):699-710

Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. *Am J Gastroenterol* 2013;108(9):1426-38

Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: part 1: diagnosis and medical management. *J Crohns Colitis* 2017;11(1):3-25

Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *J Crohns Colitis* 2016;10(3):239-54

Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J Crohns Colitis* 2017;11(7):769-84

Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). *Inflamm Bowel Dis* 2006;12(7):543-50

Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012;10(6):639-45

Klein A, Eliakim R. Non steroidal anti-inflammatory drugs and inflammatory bowel disease. *Pharmaceuticals* 2010;3(4):1084-92

Kucharzik T, Dignass A, Atreya R, et al. S3-Leitlinie – Colitis ulcerosa. Mai 2018 – AWMF-Registriernummer: 021-009. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) 2018

Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. *World J Gastroenterol* 2003;9(10):2300-7

Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015;42(4):441-51

Loftus EV, Jr., Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. *J Crohns Colitis* 2017;11(4):400-11

Lukin D, Weiss A, Aniwan S, et al. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor-antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis ECCO-Konferenz, Wien, 2018.

Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *J Crohns Colitis* 2017;11(6):649-70

Mahadevan U, Martin CF, Sandler RS, et al. 865 PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. *Gastroenterology* 2012;142(5, Supplement 1):S-149

Marits P, Landucci L, Sundin U, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. *J Crohns Colitis* 2014;8(8):881-9

Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. *Aliment Pharmacol Ther* 2014;40(6):620-8

Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *The Lancet* 2017;390(10114):2769-78

Pouillon L, Van Stappen J, Bossuyt P, et al. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? *Best Practice & Research Clinical Gastroenterology* 2018; 10.1016/j.bpg.2018.05.006

Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2009;3(2):47-91

Saidel-Odes L, Borer A, Odes S. Clostridium difficile infection in patients with inflammatory bowel disease. *Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology* 2011;24(4):263-70

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;317(26):1625-9

Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. *Aliment Pharmacol Ther* 2018;47(2):162-75

Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). *Scand J Gastroenterol* 2009;44(4):431-40

Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2016; 10.1002/14651858.CD000478.pub4(5):Cd000478

Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr* 2012;55(3):340-61

Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. *Gut* 2013;62(12):1795-805

Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. *Gastroenterology* 2014;147(5):990-1007.e3

Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and $\alpha 4\beta 7$ occupancy with response in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2018;16(5):697-705.e7

van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohns Colitis* 2015;9(2):107-24

Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology* 2008;135(4):1114-22

Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011;106(1):110-9

Velayos FS, Loftus EV, Jr., Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. *Gastroenterology* 2006;130(7):1941-9

Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. *Am J Gastroenterol* 2005;100(6):1345-53

Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and crohn's disease patients stratified by age. *Adv Ther* 2017;34(2):542-59

Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. *World J Gastroenterol* 2014;20(46):17463-7